Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 13 tags : Phase 3 save search
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.19 0.46% 0.46% 810K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
trial phase 1 phase 2 phase 3
Actinium Pharmaceuticals, Inc. Announces Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting
Published: 2021-12-13 (Crawled : 14:00) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: 4.48%
H: 0.0%
C: 0.0%
als trial phase 3
BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve
Published: 2021-12-13 (Crawled : 13:00) - biospace.com/
BCLI A | $0.531 -1.69% -1.71% 170K
|
Health Technology
|
| O: -3.36%
H: 0.0%
C: 0.0%
nurown therapeutics phase 3 als
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
zepzelca treatment trial lung cancer cancer phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.